Cardiovascular Safety Watch Column
In the January 2012 issue of the Journal for Clinical Studies, this author published a primer of non-clinical investigations for clinical scientists in the field of cardiovascular safety. While steps toward a more integrated approach throughout the entire continuum of life- cycle drug development are being made, it was noted that different components of the life-cycle cardiovascular safety continuum are still segmented in some settings. In this column J. Rick Turner of Quintiles provides an update on one of the topics discussed in that paper, namely the utilisation of human induced pluripotent stem cell-derived cardiomyocytes in the domain of cardiovascular safety.
http://jforcs.com/jcs/wp-content/uploads/2013/04/Cardiovascular-Safety-Watch-Column.pdf